Currently, clinical practice predominantly employs pharmacological agents targeting various cardiovascular conditions, such as angiotensin-converting enzyme inhibitors, β-blockers, and Ivabradine for HF; antiplatelet agents (Aspirin and Clopidogrel) and statins for MI. This evidence concerns the gene ACE and hydrops fetalis.